Table 1.

Multivariate analysis of the TUH cohort.

		HR/robust SHR (CIR) (95% CI)	Std. Err.	z	P>|z|	Statistical analysis
Event-free survival	CD36	1.55 (1.174–2.051)	0.22	3.09	0.002	**
	Age > 60 years	1.64 (1.222–2.192)	0.24	3.3	0.001	**
	WBC > 50 G/L	1.85 (1.314–2.591)	0.32	3.54	0.000	***
	Allo-SCT	0.52 (0.375–0.709)	0.08	−4.09	0.000	***
	Favorable cytogenetics	0.61 (0.361–1.03)	0.16	−1.85	0.064	ns
	Adverse cytogenetics	1.34 (0.955–1.892)	0.23	1.7	0.090	ns
	FLT3-ITD mutation	1.31 (0.938–1.832)	0.22	1.59	0.113	ns
	NPM1 mutation	0.55 (0.394–0.775)	0.10	−3.43	0.001	**
	AML secondary status	1.53 (1.134–2.06)	0.23	2.78	0.005	**
Overall survival	CD36	1.69 (1.176–2.418)	0.31	2.84	0.005	**
	Age > 60 years	1.39 (0.947–2.036)	0.27	1.68	0.093	ns
	WBC > 50 G/L	1.84 (1.192–2.833)	0.41	2.76	0.006	**
	Allo-SCT	0.30 (0.187–0.47)	0.07	−5.17	0.000	***
	Favorable cytogenetics	0.45 (0.203–1.003)	0.18	−1.95	0.051	ns
	Adverse cytogenetics	1.41 (0.903–2.204)	0.32	1.51	0.131	ns
	FLT3-ITD mutation	1.46 (0.964–2.216)	0.31	1.79	0.074	ns
	NPM1 mutation	0.61 (0.394–0.941)	0.14	−2.23	0.026	*
	AML secondary status	1.85 (1.272–2.697)	0.36	3.22	0.001	***
Cumulative incidence of relapse	CD36	1.53 (1.07–2.193)	0.28	2.33	0.020	*
	Age > 60 years	1.54 (1.088–2.192)	0.28	2.43	0.015	*
	WBC> 50 G/L	1.57 (1.008–2.458)	0.36	1.99	0.046	*
	Allo-SCT	0.77 (0.519–1.128)	0.15	−1.35	0.177	ns
	Favorable cytogenetics	0.76 (0.451–1.29)	0.20	−1.01	0.312	ns
	Adverse cytogenetics	0.86 (0.524–1.424)	0.22	−0.57	0.566	ns
	FLT3-ITD mutation	1.19 (0.763–1.869)	0.27	0.78	0.437	ns
	NPM1 mutation	0.67 (0.437–1.014)	0.14	−1.9	0.058	ns
	AML secondary status	1.37 (0.921–2.05)	0.28	1.56	0.120	ns

Note: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.

Abbreviations: Allo-SCT, allogeneic stem-cell transplantation; WBC, white blood cells.